Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28045793 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL17596884 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL7268311 | 0.83 | KDM1A (0.49) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL7268357 | 0.82 | KDM1A (0.48) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL28288627 | 0.81 | CTSK (0.56) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL26910148 | 0.81 | CTSK (0.56) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL19400126 | 0.81 | CTSK (0.56) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL7160782 | 0.81 | CTSK (0.63) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL27511368 | 0.81 | CTSK (0.63) | CTSKCTSSCTSLCTSBPSMB1 | |
| SCHEMBL608854 | 0.79 | CTSK (0.72) | CTSKCTSSCTSLCTSBPSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024203942-A1 | METHOD FOR PRODUCING RECOMBINANT PROTEIN IN BACULOVIRUS EXPRESSION VECTOR SYSTEM | デンカ株式会社 | 2024-10-03 | — | — | WO | claimed |
| US-20180117067-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS | BAYLOR RESEARCH INSTITUTE | 2018-05-03 | — | — | US | claimed |
| US-20160361279-A1 | NOVEL SIGMA RECEPTOR LIGANDS AND METHODS OF MODULATING CELLULAR PROTEIN HOMEOSTASIS USING SAME | Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine | 2016-12-15 | — | — | US | claimed |
| WO-2016160880-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS | BAYLOR RESEARCH INSTITUTE (US) | 2016-10-06 | — | — | WO | claimed |
| EP-2874997-A2 | NOVEL SIGMA RECEPTOR LIGANDS AND METHODS OF MODULATING CELLULAR PROTEIN HOMEOSTASIS USING SAME | Drexel University (US) | 2015-05-27 | — | — | EP | claimed |
| WO-2014015157-A2 | NOVEL SIGMA RECEPTOR LIGANDS AND METHODS OF MODULATING CELLULAR PROTEIN HOMEOSTASIS USING SAME | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2014-01-23 | — | — | WO | claimed |
| EP-1536777-B1 | USE OF NF-KAPPA B INHIBITORS FOR THE TREATMENT OF MASTITIS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-14 | — | — | EP | claimed |
| US-20050124590-A1 | Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2026-01-22 | — | — | US | disclosed |
| US-12454564-B2 | Compositions and methods for T cell engineering | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2025-10-28 | — | — | US | disclosed |
| US-12398108-B2 | Compounds, compositions, and methods for treating diseases | DREXEL UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4578507-A2 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | Gracell Biotechnologies (Shanghai) Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100008896-A1 | Use of Fenretinide or Bioactive Derivatives Thereof and Pharmaceutical Compositions Comprising the Same | ZHANG JI | 2010-01-14 | — | — | US | disclosed |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| EP-1536777-B1 | USE OF NF-KAPPA B INHIBITORS FOR THE TREATMENT OF MASTITIS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060240011-A1 | Use of nf-kappa b inhibitors for the treatment of mastitis | UNIVERSITE DE LIEGE (BE) | 2006-10-26 | — | — | US | disclosed |
| US-20050124590-A1 | Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | CTSK 1092/4885CTSS 652/4885CTSL 552/4885 |
| US-20050124590-A1 | Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells | NFKBIA, RELA, NFKB1 | CTSK 2404/4885CTSS 2841/4885CTSL 3229/4885 |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | CTSK 182/4885CTSS 324/4885CTSL 280/4885 |
| US-12398108-B2 | Compounds, compositions, and methods for treating diseases | SIGMAR1, OPRK1, OPRM1 | CTSK 2348/4885CTSS 1385/4885CTSL 3333/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | CTSK 3989/4885CTSS 3349/4885CTSL 3946/4885 |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | GSAP, BACE1, CD79B | CTSK 273/4885CTSS 267/4885CTSL 100/4885 |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | CTSK 3681/4885CTSS 3732/4885CTSL 3558/4885 |
| US-20160361279-A1 | NOVEL SIGMA RECEPTOR LIGANDS AND METHODS OF MODULATING CELLULAR PROTEIN HOMEOSTASIS USING SAME | TMEM97, SIGMAR1, ADRM1 | CTSK 3206/4885CTSS 2018/4885CTSL 3428/4885 |
| US-12454564-B2 | Compositions and methods for T cell engineering | PBK, CD47, MICA | CTSK 816/4885CTSS 1683/4885CTSL 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.